Christopher Boerner

Chair of the Board and Chief Executive Officer at BRISTOL MYERS SQUIBB

Board

Since November 1, 2023

Age

54 years

Education

Holds a Ph.D. and MA in business administration from the Haas School of Business at the University of California, Berkeley, and a BA in economics and history from Washington University in St. Louis.

Tenure

Joined BMY in 2015 as President and Head of U.S. Commercial Markets, later serving as President and Head of International Markets, Executive Vice President with roles including Chief Commercialization Officer and Chief Operating Officer, before being appointed Chief Executive Officer in November 2023 and elevated to Chair of the Board in April 2024.

Also at BRISTOL MYERS SQUIBB

Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer

Amanda Poole

Executive Vice President, Chief People Officer

Benjamin Hickey

President, RayzeBio Organization

About

Christopher Boerner, Ph.D., is a seasoned leader currently serving as the Chair of the Board and Chief Executive Officer at Bristol-Myers Squibb, and he is 54 years old as of February 2025. His personal background is marked by a strong academic foundation and a broad spectrum of experience in the biotechnology and pharmaceutical industries.

After joining BMY in 2015 as the President and Head of U.S. Commercial Markets, he quickly advanced through several pivotal roles, including President and Head of International Markets, and as Executive Vice President in capacities such as Chief Commercialization Officer and Chief Operating Officer. His strategic expertise and successful leadership trajectory culminated in his appointment as Chief Executive Officer on November 1, 2023, with his role further expanded when he became Chair of the Board in April 2024.

With over two decades of experience, his career includes noteworthy tenures at Seattle Genetics, Inc. and Genentech, as well as advisory roles with McKinsey & Company. His comprehensive background in healthcare, sales and marketing, and financial and risk management has played a critical role in driving transformative strategies at BMY, reinforcing his reputation as a visionary leader in the biopharma sector.

$BMY Performance Under Christopher Boerner

Past Roles

Organization	Role	Date Range	Details
Bristol Myers Squibb	Chief Executive Officer (prior to Chair)	November 2023–April 2024	Held before becoming Chair of the Board
Bristol Myers Squibb	Executive Vice President, Chief Operating Officer	April 2023–October 2023
Bristol Myers Squibb	Executive Vice President, Chief Commercialization Officer	2018–2023
Bristol Myers Squibb	President and Head of International Markets	2017–2018
Bristol Myers Squibb	President and Head of U.S. Commercial Markets	2015–2017
Seattle Genetics, Inc.	Leadership Roles	2010–2015	Held roles of increasing responsibility
Genentech	Marketing Leadership Roles	2002–2010	Served in marketing leadership roles
McKinsey & Company	Consultant for Global Pharmaceutical and Biotechnology Clients	N/A	Worked earlier in his career serving global pharmaceutical and biotechnology clients

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Annual Base Salary	$1,256,921	Annual 2023	Actual salary earned in 2023
Company Contributions to Savings Plans	$303,786	Annual 2023	Contributions to qualified and non-qualified savings plans

Performance Compensation

Data from FY 2023

Annual Target Bonus Opportunity

Metric	Value/Details	Notes
Effective Date	November 1, 2023	Base salary increased effective this date
Base Salary	$1,500,000	New base salary as of November 1, 2023
Target Bonus	150% of base salary (
$2,250,000)	Based on 150% of the revised base salary
Threshold Payout	$76,279	Minimum performance level for bonus payout
Target Payout	$1,525,579	Expected payout based on performance targets
Maximum Payout	$3,051,159	Cap on bonus payout
Performance Metrics	Aggregate In-Line & New Product Revenues and Operating Income	Total Revenues and EPS replaced by these metrics
Evaluation Period	Calendar 2023	Performance measured over the year
Payment Schedule	Annual, cash-based	No vesting schedule applies for the cash bonus

Annual Incentive Award Payment (Cash & Equity)

Metric	Value/Details	Notes
Target Incentive Award	$1,525,579	Base target for incentive award
Company Performance Factor	97.83%	Reflects performance on financial, pipeline, and ESG metrics
Actual Cash Payout	$1,567,098	Final payout after performance adjustments

Equity Incentive Plan Awards (included within long-term incentives):

Long-Term Incentive Awards

Performance Share Units (PSUs)

Metric	Value/Details	Notes
Grant Date	March 10, 2023
Grant Date Fair Value	$64.18 per unit	Represents 97.7% of the grant date closing price
Grant Date Stock Price	$65.71
Performance Metrics	Cumulative Operating Margin, In-Line & New Product Revenue, and 3-Year TSR CAGR	Weightings: 25%, 40%, 35% respectively
Payout Range	0% to 200% of target units	Depending on performance thresholds (e.g., 95%-100%-105% for Operating Margin)
Vesting Schedule	3-year cliff vesting	Vest on March 10, 2026 contingent on continuous employment and achievement of performance goals

Market Share Units (MSUs)

Metric	Value/Details	Notes
Grant Date	March 10, 2023
Grant Date Fair Value	$58.15 per unit	Represents 88.50% of grant date stock price
Grant Date Stock Price	$65.71
Performance Metric	Ratio of 10-day average closing price (measurement vs. grant date)	Minimum payout factor is 80%; maximum is 225%
Vesting Schedule	4 equal annual installments	Vest on anniversaries of the grant date from 2024 to 2027

Additional Long-Term Award (Post-Promotion to CEO)

Metric	Value/Details	Notes
Effective Date	November 1, 2023	Award upon promotion to CEO
Award Value	$1,600,000 total	Split into PSUs and MSUs
PSUs Component	$664,204 total	Vest on November 1, 2026
MSUs Component	$503,135 total	Vest in four equal installments from 2024 to 2027

These components collectively form the performance compensation for 2023. They include both cash-based bonus mechanisms and share-based awards, each with specific performance metrics, thresholds, targets, and vesting schedules as detailed above.